ORINF: AI 评分 63/100 — AI 分析 (4月 2026)

Orion Oyj is a Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients (APIs). The company operates internationally, with a significant presence in Scandinavia and Europe.

Key Facts: AI Score: 63/100 Sector: Healthcare

公司概况

概要：

Orion Oyj, a Finnish pharmaceutical company established in 1917, develops and manufactures a diverse portfolio of human and veterinary pharmaceuticals, active pharmaceutical ingredients (APIs), and self-care products, with a global presence and a focus on innovative treatments for various therapeutic areas.

ORINF是做什么的？

Founded in 1917 and headquartered in Espoo, Finland, Orion Oyj has evolved into a prominent pharmaceutical company with a global reach. The company develops, manufactures, and markets a wide range of human and veterinary pharmaceuticals, active pharmaceutical ingredients (APIs), and self-care products. Orion's pharmaceutical product portfolio includes treatments for various therapeutic areas, such as oncology (Nubeqa for prostate cancer), Parkinson's disease (Entacapone, Stalevo, Comtess, Comtan), inflammatory pain (Burana), menopausal symptoms (Divina series), acute decompensated heart failure (Simdax), breast cancer (Fareston), antipsychotic conditions (Quetiapine products), rheumatoid arthritis and cancer (Trexan), asthma and COPD (Easyhaler product portfolio), and sedation (Dexdor, Precedex, Dexmedetomidine products). In addition to human pharmaceuticals, Orion offers a range of veterinary drugs, including Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie. The company also manufactures APIs for generic compounds and proprietary products, provides contract manufacturing services, and markets and sells drugs and products manufactured by other companies. Furthermore, Orion offers self-care products, including non-prescription medicines, cosmetics, dietary supplements, vitamins, and skincare products. The company distributes its products through various channels, including online sales.

ORINF的投资论点是什么？

Orion Oyj presents a compelling investment case based on its diversified product portfolio, strong market position in select therapeutic areas, and strategic collaborations. The company's focus on developing innovative treatments, particularly in oncology and respiratory diseases, positions it for long-term growth. With a profit margin of 26.5% and a gross margin of 64.2%, Orion demonstrates strong profitability. Key growth catalysts include the continued commercialization of Nubeqa for prostate cancer and the expansion of its Easyhaler product portfolio. Potential risks include regulatory challenges, competition from generic drugs, and the outcome of clinical trials. The company's dividend yield of 2.36% offers an additional incentive for investors.

ORINF在哪个行业运营？

Orion Oyj operates in the global pharmaceutical industry, which is characterized by intense competition, stringent regulatory requirements, and rapid technological advancements. The industry is driven by factors such as an aging population, increasing prevalence of chronic diseases, and growing demand for innovative treatments. Orion competes with other major pharmaceutical companies, including BDUUY (Bayer), BIOVF (BioDelivery Sciences International), CHJTF (Chiesi Farmaceutici), CSPCY (CSPC Pharmaceutical Group), and ERFSF (Eren Pharmaceuticals Holding). The company's focus on niche therapeutic areas and strategic collaborations helps it to differentiate itself in the competitive landscape.

Drug Manufacturers - General

Healthcare

ORINF有哪些增长机遇？

Expansion of Nubeqa Sales: Nubeqa, used for the treatment of prostate cancer, represents a significant growth opportunity for Orion. The global prostate cancer market is projected to reach $17.2 billion by 2028, driven by an aging population and increasing awareness of early detection. Orion's collaboration with Bayer for the commercialization of Nubeqa provides access to a wider market and strengthens its position in the oncology space. Continued expansion of Nubeqa sales will be a key driver of revenue growth for Orion.
Easyhaler Product Portfolio Growth: Orion's Easyhaler product portfolio, used for the treatment of asthma and COPD, offers another avenue for growth. The global asthma and COPD market is expected to reach $45.7 billion by 2027, fueled by increasing air pollution and rising prevalence of respiratory diseases. Orion's focus on developing and marketing innovative Easyhaler products positions it to capture a larger share of this growing market. The company's expertise in inhaled drug delivery and its established distribution network provide a competitive advantage.
Veterinary Drug Market Expansion: Orion's veterinary drug business presents a growth opportunity driven by the increasing pet ownership and rising demand for animal health products. The global veterinary medicine market is projected to reach $45.7 billion by 2027, driven by increasing pet ownership and rising demand for animal health products. Orion's portfolio of veterinary drugs, including Bonqat, Clevor, and Domosedan, addresses various animal health needs. Expansion into new geographic markets and the development of innovative veterinary products will drive growth in this segment.
Active Pharmaceutical Ingredients (APIs) Business: Orion's API business offers a growth opportunity driven by the increasing demand for generic drugs and the outsourcing of pharmaceutical manufacturing. The global API market is expected to reach $278.7 billion by 2030, driven by the increasing demand for generic drugs and the outsourcing of pharmaceutical manufacturing. Orion's expertise in API manufacturing and its established relationships with generic drug manufacturers position it to capitalize on this trend. The company's focus on developing and manufacturing high-quality APIs will be a key driver of growth.
Strategic Collaborations and Licensing Agreements: Orion's strategy of engaging in strategic collaborations and licensing agreements provides access to new technologies and markets. The company's licensing agreement with Tenax Therapeutics for the development of oral levosimendan (TNX-103) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF) demonstrates its commitment to innovation. Continued pursuit of strategic collaborations and licensing agreements will be crucial for expanding Orion's product portfolio and entering new therapeutic areas.

Market capitalization of $11.11 billion reflects Orion Oyj's significant presence in the pharmaceutical industry.
P/E ratio of 19.55 indicates a reasonable valuation relative to earnings.
Profit margin of 26.5% demonstrates strong profitability and efficient operations.
Gross margin of 64.2% highlights the company's ability to generate revenue from its products.
Dividend yield of 2.36% provides an attractive return for investors.

ORINF提供哪些产品和服务？

Develops and manufactures human pharmaceuticals for various therapeutic areas.
Offers veterinary drugs for animal health.
Produces active pharmaceutical ingredients (APIs) for generic and proprietary products.
Provides contract manufacturing services to other pharmaceutical companies.
Markets and sells drugs and products manufactured by other companies.
Offers self-care products, including non-prescription medicines, cosmetics, and dietary supplements.
Sells products online.

ORINF如何赚钱？

Develops and manufactures pharmaceutical products.
Generates revenue through sales of human and veterinary pharmaceuticals, APIs, and self-care products.
Enters into licensing agreements and collaborations to develop and commercialize new products.
Provides contract manufacturing services to other pharmaceutical companies.

Patients who use human pharmaceuticals.
Veterinarians and pet owners who use veterinary drugs.
Pharmaceutical companies that purchase APIs.
Consumers who purchase self-care products.

Strong brand reputation and established market presence in Finland and Scandinavia.
Diversified product portfolio across various therapeutic areas.
Expertise in pharmaceutical development, manufacturing, and marketing.
Strategic collaborations and licensing agreements with other pharmaceutical companies.

什么因素可能推动ORINF股价上涨？

Ongoing: Continued commercialization of Nubeqa for prostate cancer.
Ongoing: Expansion of the Easyhaler product portfolio for asthma and COPD.
Ongoing: Growth in the veterinary drug market.
Ongoing: Increasing demand for active pharmaceutical ingredients (APIs).
Upcoming: Potential regulatory approvals for new pharmaceutical products.

ORINF的主要风险是什么？

Potential: Regulatory challenges and pricing pressures in the pharmaceutical industry.
Ongoing: Competition from generic drugs.
Potential: Patent expirations on key products.
Potential: Clinical trial failures for new drug candidates.
Ongoing: Fluctuations in currency exchange rates.

ORINF的核心优势是什么？

Diversified product portfolio across human and veterinary pharmaceuticals.
Strong market position in Finland and Scandinavia.
Expertise in pharmaceutical development and manufacturing.
Strategic collaborations with other pharmaceutical companies.

ORINF的劣势是什么？

Reliance on key products and therapeutic areas.
Exposure to generic competition.
Limited presence in some international markets.
Dependence on collaborations for certain products.

ORINF有哪些机遇？

Expansion into new geographic markets.
Development of innovative pharmaceutical products.
Acquisition of complementary businesses.
Increased demand for veterinary drugs.

ORINF面临哪些威胁？

Regulatory changes and pricing pressures.
Competition from generic drugs.
Patent expirations.
Clinical trial failures.

ORINF的竞争对手是谁？

Bayer — Multinational pharmaceutical and life sciences company. — (BDUUY)
BioDelivery Sciences International — Specialty pharmaceutical company focused on pain management. — (BIOVF)
Chiesi Farmaceutici — Italian pharmaceutical company focused on respiratory and specialty care. — (CHJTF)
CSPC Pharmaceutical Group — Chinese pharmaceutical company with a broad range of products. — (CSPCY)
Eren Pharmaceuticals Holding — Pharmaceutical company focused on developing and commercializing innovative therapies. — (ERFSF)

Key Metrics

MoonshotScore: 63/100

Company Profile

Headquarters: Espo, Finland
Employees: 4,029

AI Insight

AI analysis pending for ORINF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Orion Oyj do?

Orion Oyj is a Finnish pharmaceutical company that develops, manufactures, and markets a wide range of human and veterinary pharmaceuticals, active pharmaceutical ingredients (APIs), and self-care products. The company's human pharmaceutical products include treatments for various therapeutic areas, such as oncology, Parkinson's disease, inflammatory pain, and respiratory diseases. Orion also offers a range of veterinary drugs for animal health. In addition, the company manufactures APIs for generic compounds and proprietary products, provides contract manufacturing services, and markets and sells drugs and products manufactured by other companies. Orion distributes its products globally, with a significant presence in Scandinavia and Europe.

What do analysts say about ORINF stock?

As of March 15, 2026, a comprehensive analyst consensus for ORINF is pending AI analysis. Investors should monitor financial news sources for updated analyst ratings and price targets. Key valuation metrics to consider include the company's P/E ratio of 19.55, profit margin of 26.5%, and dividend yield of 2.36%. Growth considerations include the continued commercialization of Nubeqa, expansion of the Easyhaler product portfolio, and growth in the veterinary drug market. Investors should conduct their own due diligence and consider their individual investment objectives before making any investment decisions.

What are the main risks for ORINF?

Orion Oyj faces several risks inherent to the pharmaceutical industry. These include regulatory challenges and pricing pressures, competition from generic drugs, patent expirations on key products, and the potential for clinical trial failures for new drug candidates. As an OTC-traded stock, ORINF also faces risks related to limited financial disclosure, lower liquidity, and increased price volatility. Additionally, fluctuations in currency exchange rates can impact the company's financial performance, given its global operations. Investors should carefully consider these risks before investing in ORINF.